human
coronavirus
cov
includ
known
decad
sever
acut
respiratori
syndrom
sar
cov
briefli
emerg
human
popul
control
anoth
novel
sever
human
pathogen
covth
middl
east
respiratori
syndrom
mer
covwa
identifi
kingdom
saudi
arabia
human
case
record
five
year
target
research
remain
key
develop
control
strategi
merscov
caus
mild
ill
camel
reservoir
new
therapeut
toolbox
develop
respons
mer
also
teach
us
cov
caus
diseas
travelrel
case
continu
challeng
world
surveil
respons
capabl
data
need
understand
unexplain
primari
transmiss
sign
genet
chang
record
remain
unclear
whether
impact
clinic
diseas
camel
came
carri
viru
remain
academ
control
mer
date
humantohuman
transmiss
ineffici
viru
surveil
characteris
report
key
respond
futur
chang
merscov
current
pandem
threat
spread
mainli
aid
human
habit
error
acut
respiratori
tract
infect
arti
frequent
caus
morbid
mortal
common
reason
outpati
visit
hospitalis
among
human
worldwid
rna
virus
agent
caus
arti
frequentlyusu
selflimit
upper
respiratori
tract
syndrom
coronavirus
cov
recombin
envelop
virus
long
positivesens
rna
genom
ancestr
zoonot
origin
adapt
bind
divers
rang
cellular
receptor
four
human
coronavirus
hcov
evolv
initi
bat
camelid
rodent
becom
distinct
global
endem
season
pathogen
caus
mild
moder
arti
among
human
hcov
occupi
two
four
genera
subfamili
coronavirina
human
coronaviru
subspeci
known
year
human
coronaviru
human
coronaviru
first
characteris
respect
sever
acut
respiratori
syndromerel
coronaviru
sarscov
briefli
emerg
human
popul
control
known
circul
today
brief
sever
emerg
spark
renew
studi
cov
anoth
novel
sever
pathogen
cov
identifi
kingdom
saudi
arabia
ksa
human
case
record
five
year
sarscov
new
middl
east
respiratori
syndrom
coronaviru
merscov
belong
speci
middl
east
respiratori
syndromerel
coronaviru
evolv
ancestr
differ
bat
cov
travel
histori
laboratori
analysi
would
requir
differenti
mer
sar
still
occur
date
mer
case
limit
countri
arabian
peninsula
rare
travelrel
spillov
one
case
precipit
larg
healthcar
multifacil
outbreak
republ
korea
confirm
case
mer
occur
person
irrespect
sign
symptom
laboratoryreport
merscov
infect
probabl
case
requir
minimum
clinic
diagnos
acut
febril
diseas
epidemiolog
link
partial
laboratori
diagnost
profil
briefli
review
recent
literatur
current
understand
mer
merscov
highlight
knowledg
gap
viral
receptor
merscov
transmembran
glycoprotein
call
dipeptidyl
wide
tissu
distribut
human
includ
alveolar
cell
lower
respiratori
tract
small
intestin
interact
merscov
receptorbind
domain
rbd
within
spike
fusion
protein
figur
express
upregul
lower
respiratori
tract
poor
lung
function
lower
respiratori
tract
untreat
asthma
solubl
form
plasma
obes
patient
whether
blood
born
interfer
merscov
revers
bind
contribut
system
distribut
merscov
seriou
diseas
question
worthi
investig
studi
upper
respiratori
tract
found
littl
sign
express
level
tissu
distribut
although
one
studi
identifi
enzymat
activ
suggest
present
may
use
expand
search
express
tissu
indic
case
differ
diseas
state
coinfect
especi
virus
known
inflam
lower
respiratori
tract
trigger
asthma
exacerb
rhinovirus
also
interest
merscov
may
also
use
sialic
acid
lowaffin
select
cellular
receptor
aid
attach
entri
posit
cell
receptor
bind
fusion
cell
antigen
trimer
mer
well
characteris
respiratori
diseas
human
extens
inflamm
immun
evas
hallmark
sever
diseas
ascrib
cov
among
confirm
mer
case
fever
cough
dyspnoea
common
clinic
manifest
mean
incub
period
mer
day
longer
period
associ
reduc
risk
death
merscov
infect
also
result
mild
subclin
outcom
typic
mer
case
saudi
male
age
year
often
present
hospit
pneumonia
wors
sever
mer
occur
frequent
among
comorbid
includ
diabet
mellitu
cirrhosi
other
affect
respiratori
renal
cardiac
system
downregul
innat
immun
respons
mediat
associ
disord
may
relat
sever
mer
may
high
frequenc
sever
mer
reflect
elev
preval
certain
comorbid
middl
east
region
comorbid
featur
among
sar
case
among
case
mer
merscov
highli
opportunist
pathogen
june
outbreak
republ
korea
found
confirm
case
present
fever
cough
upper
respiratori
tract
sign
symptom
progress
within
week
lower
respiratori
tract
distress
lymphopenia
elev
liver
enzym
mer
progress
acut
respiratori
distress
syndrom
multiorgan
system
failur
requir
intens
support
care
extra
pulmonari
infect
occur
like
result
haematogen
transport
viru
area
need
studi
similarli
littl
known
sequela
follow
merscov
infect
one
studi
surviv
acut
respiratori
distress
syndrom
well
one
year
later
anoth
studi
identifi
delay
neurolog
manifest
treatment
mer
case
lack
longterm
followup
death
occur
among
mer
case
approxim
case
ksa
case
republ
korea
mortal
rang
among
younger
age
group
among
age
year
among
studi
fatal
case
death
occur
day
symptom
onset
extent
subclin
mild
infect
commun
remain
unquantifi
mortal
figur
may
overestim
merscov
variant
exist
singl
antigen
group
lineag
c
genu
betacoronaviru
merscov
infect
subclin
less
sever
humor
immun
respons
may
weak
delay
shortliv
undetect
human
still
reinfect
preexist
neutralis
antibodi
similarli
seen
camel
howev
survivor
symptomat
mer
develop
antibodi
includ
neutralis
antibodi
declin
persist
year
whether
antibodi
prevent
futur
infect
remain
examin
mild
subclin
mer
still
develop
tcell
respons
survivor
sever
mer
includ
mount
antibodi
respons
develop
tcell
respons
robust
laboratorybas
realtim
rtpcr
diagnost
tool
describ
immedi
merscov
discov
remain
reliabl
sever
differ
researchbas
antibodi
detect
protocol
also
report
human
anim
studi
molecular
serolog
kit
commerci
avail
current
molecular
method
rapid
mani
step
combin
delay
public
final
test
result
initi
decis
request
merscov
test
sampl
collect
nucleic
acid
extract
pcr
addit
sampl
repeat
test
report
process
molecular
rapid
sensit
pointofcar
test
poct
avail
would
help
support
infect
control
healthcar
set
world
health
organis
recommend
test
appropri
sampl
merscov
rna
use
realtim
rtpcr
method
subgenom
sequenc
confirm
screen
result
necessari
repeat
test
often
requir
viru
isol
cultur
recommend
tool
detect
antibodi
merscov
may
use
identifi
seroconvers
defin
probabl
case
confirm
rtpcr
unsuccess
imposs
mild
subclin
mer
case
report
among
younger
peopl
includ
healthcar
worker
children
remain
unclear
proport
merscov
infect
truli
subclin
one
studi
found
mani
initi
incorrectli
classifi
difficulti
identifi
use
diagnost
antibodi
respons
mild
subclin
diseas
mean
seropreval
studi
like
underreport
histori
merscov
merscov
specif
test
may
help
use
serolog
need
clarif
human
incident
host
merscov
princip
natur
reservoir
host
merscov
dromedari
camel
among
camel
merscov
infect
manifest
manner
similar
common
cold
manifest
human
camel
upper
respiratori
tract
express
high
level
receptor
studi
merscov
highlight
need
collabor
polit
divers
basic
appli
field
research
humananim
interfacea
one
health
approach
camel
trade
play
central
role
movement
infect
host
around
arabian
peninsula
pakistan
north
west
east
africa
harbour
merscovinfect
camel
alpaca
llama
pig
potenti
host
accord
experiment
evid
addit
alpaca
found
natur
infect
viru
genet
detect
biolog
cultur
human
nearli
ident
isol
camel
instanc
use
identifi
transmiss
rout
sign
viru
chang
appear
continu
surveil
time
recombin
identifi
variat
region
tropismdefin
spike
protein
diverg
egyptian
camel
merscov
variant
associ
reduc
infect
vitro
compar
human
less
diverg
camel
merscov
variant
nearli
human
anim
merscov
genom
sequenc
produc
merscov
infect
sinc
studi
function
impact
identifi
mutat
conduct
among
mersrel
coronavirus
may
exist
three
conspecif
virus
camel
merscov
bat
cov
relat
distinct
genom
diverg
spike
gene
ongo
viral
surveil
characteris
essenti
ensur
variant
increas
effici
attach
fusion
replic
emerg
unnot
surveil
human
respiratori
ill
merscovposit
camel
countri
outsid
arabian
peninsula
current
lack
accord
ksa
ministri
health
nearli
half
mer
case
classifi
primari
case
zoonos
origin
direct
indirect
contact
infect
dromedari
camel
unidentifi
sourc
link
known
human
case
precis
mechan
merscov
spread
camel
human
unknown
essenti
enact
precaut
reduc
exposur
infect
anim
secondari
case
make
slightli
half
mer
case
mostli
result
exposur
associ
healthcar
facil
infecti
merscov
presum
found
droplet
model
also
suggest
possibl
airborn
spread
viru
remain
viabl
least
h
plastic
steel
surfac
presum
underpin
extens
contamin
air
surfac
hospit
hous
patient
mer
viru
appear
sensit
standard
heat
chemic
inactiv
measur
antibodi
merscov
found
camel
sera
far
back
anim
antibodi
merscov
shortliv
prevent
reinfect
human
contact
camel
often
associ
collect
prepar
ingest
camel
milk
meat
femal
camel
especi
bred
milk
highest
rate
merscov
seroposit
merscov
rna
detect
milk
one
studi
viru
found
stabl
spike
milk
sampl
anoth
studi
camel
larger
herd
higher
rate
seroposit
compar
smaller
herd
femal
young
camel
also
higher
rate
merscov
rna
older
male
camel
evid
human
infect
result
ingest
present
found
experiment
inocul
human
intestin
cell
organoid
host
product
merscov
infect
merscov
remain
infecti
transit
gastric
acid
intestin
respiratori
neurolog
infect
follow
intragastr
inocul
transgen
mice
whether
camel
milk
meat
actual
contain
suitabl
infecti
dose
caus
intestin
infect
human
yet
determin
seem
like
process
milk
butcheri
may
contamin
surfac
gener
infecti
droplet
includ
suffici
inoculum
human
infect
could
result
via
inhal
selfinocul
known
whether
eye
act
portal
merscov
entri
sinc
major
humantohuman
merscov
infect
associ
healthcar
improv
infect
control
prevent
consid
key
prevent
outbreak
among
human
occup
risk
exposur
infect
anim
outbreak
republ
korea
case
respons
transmiss
event
new
case
result
identifi
onward
transmiss
reproduct
r
number
calcul
select
ksa
outbreak
three
five
case
cough
prolong
exposur
crowd
larg
number
contact
import
factor
disproportion
viru
transmiss
role
mild
subclin
merscov
infect
maintain
viru
human
popul
convincingli
address
healthcar
worker
found
shed
viral
rna
five
week
absenc
diseas
add
urgenc
need
studi
none
among
contact
mildli
symptomat
merscovinfect
healthcar
worker
seroconvert
mention
whether
index
case
seroconvert
ksa
hospit
outbreak
investig
contact
subclin
merscovinfect
healthcar
worker
becam
rtpcr
posit
suggest
transmiss
possibl
studi
report
rare
camel
contact
among
human
case
histori
contact
merscovinfect
human
rais
question
primari
case
acquir
infect
commun
spread
subclin
transmiss
need
attent
hajj
pilgrimag
annual
mass
gather
ksa
provid
mani
opportun
merscov
transmit
spread
global
howev
rhinovirus
influenza
virus
season
respiratori
virus
date
driven
bulk
respiratori
diseas
associ
hajj
indirectli
reinforc
merscov
transmit
effici
among
human
outdoor
hospit
environ
healthcar
worker
patient
carer
experi
prolong
exposur
infecti
case
absenc
suitabl
person
protect
equip
ppe
usual
becom
infect
exampl
rule
wherebi
rel
infect
individu
respons
disproportion
number
new
case
insuffici
clean
room
surfac
inadequ
room
ventil
overcrowd
also
suggest
drive
indoor
merscov
transmiss
specif
antivir
licens
vaccin
avail
cov
infect
human
rang
candid
exist
even
merscov
infect
rare
transmit
poorli
evolv
becom
pandem
threat
serv
use
role
drive
vaccin
research
cov
current
yet
emerg
case
healthcar
facil
improv
hand
hygien
use
ppe
glove
gown
respiratori
eye
protect
surfac
clean
help
disrupt
transmiss
rapid
triag
febril
patient
respiratori
sign
symptom
prevent
merscov
infect
dromedari
camel
precaut
includ
avoid
contact
camel
nasal
secret
cook
camel
meat
pasteuris
camel
milk
studi
better
quantifi
risk
attach
potenti
pathway
vaccin
prevent
cov
diseas
requir
humor
cellular
immun
airway
immun
respons
may
key
prevent
establish
human
merscov
infect
localis
deposit
aerosolis
vaccin
could
prove
use
number
vaccin
platform
payload
proceed
although
progress
challeng
need
anim
model
suitabl
reconstitut
human
lower
respiratori
tract
diseas
show
evid
prevent
effect
candid
progress
clinic
trial
spike
protein
rbd
elicit
neutralis
antibodi
respons
employ
payload
number
platform
includ
dna
vaccin
modifi
vaccinia
viru
ankara
measl
viru
human
chimpanzeeadenovirusbas
vector
also
venezuelan
equin
enceph
replicon
express
nucleocapsid
nanoparticl
structur
nonstructur
delet
mutant
merscov
vaccin
camel
like
rapid
least
expens
best
intervent
prevent
rare
spillov
becom
amplifi
human
healthcar
set
success
report
approach
challeng
problem
camel
natur
reinfect
merscov
even
presenc
high
titr
neutralis
antibodi
date
camel
vaccin
reduc
viral
load
prevent
viru
shed
human
vaccin
could
target
occup
atrisk
group
includ
healthcar
farm
barn
market
slaughterhous
worker
widespread
applic
mer
vaccin
time
seem
warrant
rariti
seroposit
donor
sometim
low
antibodi
titr
lack
clinic
evid
made
use
convalesc
sera
recov
mer
patient
possibl
treatment
one
signific
limit
instead
human
monoclon
antibodi
target
rbd
polyclon
antibodi
may
provid
treatment
option
risk
sever
outcom
clinic
trial
await
earli
control
viral
replic
import
administr
interferon
ifn
ribavirin
ifn
combin
within
hour
initi
show
promis
practic
use
human
challeng
infect
healthcar
set
human
usual
present
care
well
advanc
diseas
combin
treatment
reduc
viral
replic
host
immun
respons
like
valuabl
develop
wide
rang
repurpos
novel
potenti
antivir
includ
polymeras
nucleotid
synthesi
proteas
inhibitor
fusioninhibit
peptid
investig
corticosteroid
use
recommend
acut
respiratori
distress
syndrom
compar
studi
randomis
control
trial
mostli
lack
though
much
alreadi
known
remain
import
clarifi
rout
human
infect
includ
role
eye
contract
infect
among
primari
human
case
develop
rapid
molecular
poct
test
altern
serolog
detect
help
us
understand
merscov
transmiss
lead
reduct
outbreak
scale
mild
subclin
case
among
nonhospitalis
arabian
peninsula
commun
unknown
role
transmiss
knowledg
mer
come
studi
hospitalbas
popul
link
commun
contact
futur
prospect
longterm
cohort
studi
mild
commun
respiratori
ill
use
molecular
method
would
use
children
far
larg
absent
mer
case
talli
may
repres
import
popul
prospect
studi
recent
lesson
zika
ebola
virus
also
inform
new
studi
seek
possibl
longterm
sequela
viral
persist
highlight
need
followup
sever
mer
patient
septemb
merscov
pass
fifth
year
sinc
discoveri
remain
rare
caus
diseas
geograph
defin
region
world
known
concurr
presenc
infect
camel
host
much
know
mer
relat
sever
diseas
travelrel
case
continu
challeng
rest
world
surveil
respons
capabl
need
data
understand
unexplain
primari
transmiss
sign
genet
chang
merscov
record
remain
unclear
whether
chang
clinic
diseas
camel
came
carri
viru
live
today
remain
unknown
academ
control
mer
date
humantohuman
transmiss
ineffici
viru
surveil
characteris
ensur
chang
statu
quo
identifi
merscov
current
pandem
threat
spread
aid
human
habit
error
nevertheless
much
need
therapeut
toolbox
develop
process
learn
cov
caus
diseas
confound
immun
respons
come
prevent
treat
respiratori
infect
focus
research
need
minimis
impact
mer
base
control
strategi
evid
glean
specif
address
relev
unknown
